Lefamulin
Indications
Lefamulin is used for:
Indicated for treatment of, community-acquired bacterial pneumonia (CABP), in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae
Adult Dose
Community Acquired Bacterial Pneumonia
Indicated for treatment of community-acquired bacterial pneumonia (CABP) in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae
150 mg IV q12hr OR
600 mg PO q12 hr
Duration of treatment: 5-7 days
Child Dose
Renal Dose
Administration
Contra Indications
Lefamulin should not be used in patients with known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta.
Precautions
Lefamulin has the potential to cause a change on an ECG reading (prolonged QT interval). Patients with prolonged QT interval, patients with certain irregular heart rhythms (arrhythmias), patients receiving treatment for certain irregular heart rhythms (antiarrhythmic agents), and patients receiving other drugs that prolong the QT interval should avoid lefamulin.
Pregnancy-Lactation
Pregnancy
Based on animal studies, may cause fetal harm
Verify pregnancy status in women of reproductive potential before starting treatment
Animal studies
Animal studies indicate that IV administration during organogenesis resulted in an increased incidence of prenatal mortality at mean maternal exposures 0.9 times the mean exposure in clinical patients (based on AUC[0-24h]), decreased fetal body weights, apparent delay in sexual maturation that suggests treatment-related developmental delay, and malformations
Contraception
Advise females of reproductive potential to use contraception during treatment and for 2 days after final dose
Lactation
No data are available on the presence of lefamulin in human milk, the effects on the breastfed infant, or the effects on milk production
Available data in animals have shown lefamulin excreted in milk
If a drug is present in animal milk, it is likely the drug will be present in human milk
Owing to the potential for serious adverse effects, instruct lactating women to pump and discard milk for the duration of treatment and for 2 days after final dose
Interactions
Adverse Effects
Side effects of Lefamulin :
The most common adverse reactions reported in patients taking lefamulin included diarrhea, nausea, reactions at the injection site, elevated liver enzymes and vomiting.
Mechanism of Action
First-in-class semi-synthetic pleuromutilin antibiotic; selectively inhibits bacterial translation by binding to the peptidyl transferase component of the ribosome 50S subunit